Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Non-Current Assets (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Non-Current Assets for 10 consecutive years, with $19.8 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 59.14% to $19.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $168.5 million through Dec 2025, down 45.05% year-over-year, with the annual reading at $19.8 million for FY2025, 59.14% down from the prior year.
  • Non-Current Assets for Q4 2025 was $19.8 million at Rein Therapeutics, down from $48.5 million in the prior quarter.
  • The five-year high for Non-Current Assets was $87.7 million in Q4 2023, with the low at $29000.0 in Q3 2023.
  • Average Non-Current Assets over 5 years is $28.3 million, with a median of $363000.0 recorded in 2021.
  • The sharpest move saw Non-Current Assets tumbled 94.81% in 2021, then surged 294841.38% in 2024.
  • Over 5 years, Non-Current Assets stood at $304000.0 in 2021, then crashed by 55.92% to $134000.0 in 2022, then skyrocketed by 65379.1% to $87.7 million in 2023, then plummeted by 44.69% to $48.5 million in 2024, then crashed by 59.14% to $19.8 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $19.8 million, $48.5 million, and $50.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.